Conjunctival structure of glaucomatous eyes treated with anti-glaucoma eye drops: a cross-sectional study using anterior segment optical coherence tomography

Table 2 The univariate and general linear mixed model (GLMM) analyses on the conjunctival epithelium/conjunctival stroma preservation rate

a. The effects of background characteristics
	Univariable analysis		Multiple analysis 1
	β	p-value	β	p-value	VIF
Sex (male vs. female)	−0.051	0.281	−0.058	0.234	1.08
Age (years)	−0.114	0.033	−0.114	0.038	1.06
Number of anti-glaucoma eye drops	−0.045	0.326	−0.089	0.132	1.74
Duration of administration (months)	0.015	0.768	0.078	0.227	1.72
b. The effects of anti-glaucoma eye drops
	Univariable analysis		Multiple analysis 2
	β	p-value	β	p-value
Prostaglandin analogs	−0.046	0.331	− 0.047	0.299
α2-receptor agonist	−0.065	0.160	−0.064	0.161
Rho kinase inhibitor	0.031	0.440	0.028	0.488
The fixed combination of β-blockers/CAIs	−0.025	0.564	−0.024	0.579
The fixed combination of β-blockers/prostaglandin analogs	−0.052	0.303	−0.050	0.313
β-blockers	0.012	0.821	0.006	0.909
CAIs	−0.038	0.449	−0.048	0.333

Multiple analysis 1, multiple GLMM analysis with the preservation rate and with background characteristics; Multiple analysis 2, multiple GLMM analysis with the preservation rate and with the eye drops after adjusted for confounding factor (age)
CAI carbonic anhydrase inhibitors, VIF variance inflation factor

ISSN: 1471-2415